Interestingly, Koh et al. [48] suggested that higher levels of FoxP3+ Treg cells can predict a beneficial response to anti-PD-1 immunotherapy in patients with advanced non-small cell lung cancer, and this observation can rationalize our results. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.